Voglio sapere a riguardo di…

Federal Register / Vol. 86, No. 87 / Friday, May 7, 2021 / Notices informed dietary choices and construct healthful diets. We intend to use the results to inform our continued exploration of a symbol manufacturers could voluntarily use to represent the
nutrient content claim healthy on the food label. We will not use the results to develop population estimates.
Description of Respondents:
Respondents to this collection of
24631

information include members of the general public.
FDA estimates the burden of this collection of information as follows:

TABLE 1ESTIMATED ANNUAL REPORTING BURDEN 1
Number of respondents
Activity Study er.
Study Study Study Study Study Study Study Study
Number of responses per respondent
Total annual responses
Average burden per response
Total hours
1 Experiment Cognitive interview screen-

75

1

75

0.083 5 minutes

6

Survey Cognitive interview screener 2 ..
Experiment Cognitive interview
Survey Cognitive interview
Experiment Pretest
Survey Pretest 2
Experiment
Survey
Survey

75
9 5
180
25
5,000
1,000
1,000

1
1 1
1 1
1 1
1

75
9 5
180
25
5,000
1,000
1,000

0.083 5 minutes
1
1
0.25 15 minutes
0.17 10 minutes
0.25 15 minutes
0.17 10 minutes
0.17 10 minutes

6
9 5
45
4 1,250
170
170

Total

1,665

2
1 2
1 2
1 2
3

1 There 2 Since
are no capital costs or operating and maintenance costs associated with this collection of information.
Study 3 is identical to Study 2, only one set of cognitive interviews and pretests are needed.

Dated: April 30, 2021.
Lauren K. Roth, Acting Principal Associate Commissioner for Policy.
FR Doc. 202109622 Filed 5621; 8:45 am BILLING CODE 416401P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration Docket No. FDA2021N0357

Pharmacy Compounding Advisory Committee; Notice of Meeting;
Establishment of a Public Docket;
Request for Comments AGENCY:

Food and Drug Administration,
HHS.
Notice; establishment of a public docket; request for comments.

ACTION:

The Food and Drug Administration FDA or the Agency announces a forthcoming public advisory committee meeting of the Pharmacy Compounding Advisory Committee. The general function of the committee is to provide advice on scientific, technical, and medical issues concerning drug compounding under the Federal Food, Drug, and Cosmetic Act FD&C Act, and, as required, any other product for which FDA has regulatory responsibility, and to make appropriate recommendations to the Agency. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.

SUMMARY:

VerDate Sep<11>2014

19:55 May 06, 2021

Jkt 253001

The meeting will be held on June 9, 2021, from 10 a.m. to 5:05 p.m.
Eastern Time.
ADDRESSES: Please note that due to the impact of the COVID19 pandemic, all meeting participants will be joining this advisory committee meeting via an online teleconferencing platform.
Answers to commonly asked questions about FDA advisory committee meetings may be accessed at: https
www.fda.gov/AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm408555.htm.
FDA is establishing a docket for public comment on this meeting. The docket number is FDA2021N0357.
The docket will close on June 8, 2021.
Submit either electronic or written comments on this public meeting by June 8, 2021. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before June 8, 2021.
The https www.regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of June 8, 2021. Comments received by mail/hand delivery/courier for written/paper submissions will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date.
Comments received on or before May 26, 2021, will be provided to the committee. Comments received after that date will be taken into consideration by FDA. In the event that the meeting is cancelled, FDA will continue to evaluate any relevant applications or information, and DATES:

PO 00000

Frm 00050

Fmt 4703

Sfmt 4703

consider any comments submitted to the docket, as appropriate.
You may submit comments as follows:
Electronic Submissions Submit electronic comments in the following way:
Federal eRulemaking Portal:
https www.regulations.gov. Follow the instructions for submitting comments.
Comments submitted electronically, including attachments, to https
www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone elses Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https www.regulations.gov.
If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed see Written/Paper Submissions and Instructions.
Written/Paper Submissions Submit written/paper submissions as follows:
Mail/Hand Delivery/Courier for written/paper submissions: Dockets Management Staff HFA305, Food and
E:FRFM07MYN1.SGM

07MYN1